US8951504 — (trimethoxyphenylamino) pyrimidinyl formulations
Method of Use · Assigned to Rigel Pharmaceuticals Inc · Expires 2032-07-27 · 6y remaining
What this patent protects
This patent protects pharmaceutical compositions containing a compound of Formula (I) and one or more effervescent agents, along with other ingredients.
USPTO Abstract
There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2294 |
— | fostamatinib-disodium |
U-2294 |
— | fostamatinib-disodium |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.